Canaccord Genuity Reiterates a 'Hold' on Vertex (VRTX); Telaprevir + VX-222, IFN-free Combo Faces Another Challenge in All-Oral Quest
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Hold' on Vertex (NASDAQ: VRTX), PT $35.
Canaccord analyst says, "We think the company’s update yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We think the company’s update yesterday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
